PT101 is an engineered IL-2 mutein fused to a protein backbone, and is vying to come to market along with other IL-2-based therapies, notably Eli Lilly and Nektar Therapeutics’ phase 2 candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback